Un equipo de la Universidad de Indiana señala a la enzima IDOL para tratar el alzhéimer

Investigadores de la Facultad de Medicina de la Universidad de Indiana han identificado a la enzima IDOL como una posible nueva diana terapéutica para tratar la enfermedad de Alzheimer. Estudios de laboratorio demostraron que la eliminación de esta enzima en las neuronas redujo las placas amiloides y mejoró la comunicación entre las células cerebrales.

Los hallazgos, publicados en la revista Alzheimer's & Dementia, provienen de experimentos realizados con modelos animales de la enfermedad. La eliminación del gen IDOL en las neuronas redujo los niveles de placa y disminuyó la apolipoproteína E, una proteína vinculada a un mayor riesgo de alzhéimer. Los efectos fueron más pronunciados en las neuronas que en la microglía, las células inmunitarias del cerebro, contrariamente a lo que se esperaba inicialmente.

Artículos relacionados

Microscopic illustration of protective microglia clearing amyloid plaques in an Alzheimer's brain model due to the OLE molecule
Imagen generada por IA

Study identifies OLE molecule that shifts microglia into a more protective state in Alzheimer’s models

Reportado por IA Imagen generada por IA Verificado por hechos

Researchers in Spain and Switzerland report that an experimental molecule called OLE helped restore protective behavior in the brain’s immune cells in animal models of Alzheimer’s disease, reducing amyloid-related pathology and improving performance on memory and movement tests.

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

Reportado por IA

Researchers at Cold Spring Harbor Laboratory have found that blocking the protein PTP1B improves memory and boosts plaque clearance in mouse models of Alzheimer's disease. The discovery links the protein to brain immune function and metabolic risks like diabetes and obesity. The team aims to develop inhibitors for potential human treatments.

Researchers have identified a previously unknown mechanism called karyoptosis that appears to drive the death of brain cells in Alzheimer's disease and frontotemporal dementia. The discovery, based on analysis of human brain tissue, points to a potential new target for treatments aimed at slowing neuron loss.

Reportado por IA

Researchers at UCLA have identified senescent immune cells, dubbed 'zombie' cells, that accumulate in aging livers and contribute to fatty liver disease. By eliminating these cells in mice, the team reversed liver damage and reduced body weight, even on an unhealthy diet. The findings, published in Nature Aging, suggest similar mechanisms may drive human liver conditions.

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar